We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Q4 Earnings Miss, International Sales Rise
Read MoreHide Full Article
McKesson (MCK - Free Report) reported fourth-quarter fiscal 2018 earnings of $3.49 per share, missing the Zacks Consensus Estimate of $3.54. Earnings, however, improved from the year-ago quarter’s figure by 2.3%.
McKesson posted sales of $51.63 billion, marginally missing the Zacks Consensus Estimate of $51.64 billion and up 4% at constant currency (cc).
Quarter in Detail
McKesson operates through two segments — Distribution Solutions and Technology Solutions. However, in the reported quarter, the company did not report any detail of the Technology Solutions unit.
Distribution Solutions
The segment reported revenues of $51.63 billion in the quarter, up 5% at cc. In fact, this segment accounted for the whole of the company’s fourth-quarter revenues.
McKesson Corporation Price, Consensus and EPS Surprise
North America pharmaceutical distribution & services revenues came in at $42.73 billion, up 5.1% from the prior-year quarter. Full-year revenues at the segment totaled $174.19 billion, up 6% at cc. The rise can be attributed to market growth and acquisitions, which have been partially offset by branded to generic conversions.
International pharmaceutical distribution & services reported revenues of $7.28 billion, which increased 18.6% from the year-ago quarter. Full-year revenues at the segment were $27.32 billion, up 5% at cc.
Medical-Surgical distribution & services raked in revenues of $1.73 billion, which improved 8.7% on a year-over-year basis. In the full year, the segment posted revenues worth $6.61 billion, up 6% from a year ago.
Margins
Gross profit in the reported quarter was $2.98 billion, up 1.1% on a year-over-year basis.
Gross margin was 5.8%, down 30 basis points (bps).
Operating expenses rose 6.9% on a year-over-year basis to $2.06 billion.
FY18 at a Glance
Full-year adjusted earnings per share of $12.62 grew from $12.54 a year ago, including 31 cents per diluted share contribution to create a non-profit foundation. The reported figure missed the Zacks Consensus Estimate, which is pegged at $12.69.
Revenues in fiscal 2018 grossed $208.36 billion, compared with $198.5 billion a year ago. This figure marginally missed the Zacks Consensus Estimate which is pinned at $208.43 billion.
Fiscal 2018 cash flow from operations totaled $4.3 billion. McKesson ended the year with cash and cash equivalents of $2.7 billion.
In fiscal 2018, McKesson repaid approximately $765 million of net long-term debt.
Share Repurchase Update
The company’s board of directors authorized an additional $4.0 billion of share repurchase program.
Guidance
McKesson expects adjusted earnings per share of $13.00-$13.80 for fiscal 2019. Notably, the Zacks Consensus Estimate for fiscal 2019 earnings is pegged at $13.39, within the given range.
Free cash flow is expected at around $3.0 billion for fiscal 2019.
The guidance assumes full-year adjusted tax rate of approximately 21% to 23%, which may vary from quarter to quarter.
Per management, the fiscal 2019 outlook represents mid- to high-single digit percentage growth year over year, reflecting more stable market conditions.
Our Take
McKesson wrapped up fourth-quarter fiscal 2018 on a mixed note, wherein adjusted earnings and revenues missed estimates. Moreover, solid growth in the Distribution Solutions segment holds promise. The surge in international sales is a major positive. However, contracting gross margins raise concern. Escalating operating expenses is also a headwind. Price fluctuation of generic pharmaceuticals and stiff competition in niche space add to the woes.
Zacks Rank & Key Picks
McKesson currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks which reported solid results this earnings season are Intuitive Surgical (ISRG - Free Report) , Abiomed, Inc. and Varian Medical Systems . While Intuitive Surgical and Abiomed sport a Zacks Rank #1 (Strong Buy), Varian Medical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Abiomed reported fourth-quarter fiscal 2018 earnings per share of 80 cents, which beat the Zacks Consensus Estimate by 25%. Revenues were $174.4 million, beating the Zacks Consensus Estimate by 6.3%.
Varian Medical reported second-quarter fiscal 2018 adjusted earnings per share of $1.15, which beat the Zacks Consensus Estimate of $1.06. Revenues totaled $729.9 million, which surpassed the Zacks Consensus Estimate of $659.6 million.
Intuitive Surgical reported first-quarter 2018 adjusted earnings per share of $2.44, which beat the Zacks Consensus Estimate by 22.6%. Revenues totaled $848 million, also surpassing the Zacks Consensus Estimate by 10.6%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
McKesson (MCK) Q4 Earnings Miss, International Sales Rise
McKesson (MCK - Free Report) reported fourth-quarter fiscal 2018 earnings of $3.49 per share, missing the Zacks Consensus Estimate of $3.54. Earnings, however, improved from the year-ago quarter’s figure by 2.3%.
McKesson posted sales of $51.63 billion, marginally missing the Zacks Consensus Estimate of $51.64 billion and up 4% at constant currency (cc).
Quarter in Detail
McKesson operates through two segments — Distribution Solutions and Technology Solutions. However, in the reported quarter, the company did not report any detail of the Technology Solutions unit.
Distribution Solutions
The segment reported revenues of $51.63 billion in the quarter, up 5% at cc. In fact, this segment accounted for the whole of the company’s fourth-quarter revenues.
McKesson Corporation Price, Consensus and EPS Surprise
McKesson Corporation Price, Consensus and EPS Surprise | McKesson Corporation Quote
North America pharmaceutical distribution & services revenues came in at $42.73 billion, up 5.1% from the prior-year quarter. Full-year revenues at the segment totaled $174.19 billion, up 6% at cc. The rise can be attributed to market growth and acquisitions, which have been partially offset by branded to generic conversions.
International pharmaceutical distribution & services reported revenues of $7.28 billion, which increased 18.6% from the year-ago quarter. Full-year revenues at the segment were $27.32 billion, up 5% at cc.
Medical-Surgical distribution & services raked in revenues of $1.73 billion, which improved 8.7% on a year-over-year basis. In the full year, the segment posted revenues worth $6.61 billion, up 6% from a year ago.
Margins
Gross profit in the reported quarter was $2.98 billion, up 1.1% on a year-over-year basis.
Gross margin was 5.8%, down 30 basis points (bps).
Operating expenses rose 6.9% on a year-over-year basis to $2.06 billion.
FY18 at a Glance
Full-year adjusted earnings per share of $12.62 grew from $12.54 a year ago, including 31 cents per diluted share contribution to create a non-profit foundation. The reported figure missed the Zacks Consensus Estimate, which is pegged at $12.69.
Revenues in fiscal 2018 grossed $208.36 billion, compared with $198.5 billion a year ago. This figure marginally missed the Zacks Consensus Estimate which is pinned at $208.43 billion.
Fiscal 2018 cash flow from operations totaled $4.3 billion. McKesson ended the year with cash and cash equivalents of $2.7 billion.
In fiscal 2018, McKesson repaid approximately $765 million of net long-term debt.
Share Repurchase Update
The company’s board of directors authorized an additional $4.0 billion of share repurchase program.
Guidance
McKesson expects adjusted earnings per share of $13.00-$13.80 for fiscal 2019. Notably, the Zacks Consensus Estimate for fiscal 2019 earnings is pegged at $13.39, within the given range.
Free cash flow is expected at around $3.0 billion for fiscal 2019.
The guidance assumes full-year adjusted tax rate of approximately 21% to 23%, which may vary from quarter to quarter.
Per management, the fiscal 2019 outlook represents mid- to high-single digit percentage growth year over year, reflecting more stable market conditions.
Our Take
McKesson wrapped up fourth-quarter fiscal 2018 on a mixed note, wherein adjusted earnings and revenues missed estimates. Moreover, solid growth in the Distribution Solutions segment holds promise. The surge in international sales is a major positive. However, contracting gross margins raise concern. Escalating operating expenses is also a headwind. Price fluctuation of generic pharmaceuticals and stiff competition in niche space add to the woes.
Zacks Rank & Key Picks
McKesson currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks which reported solid results this earnings season are Intuitive Surgical (ISRG - Free Report) , Abiomed, Inc. and Varian Medical Systems . While Intuitive Surgical and Abiomed sport a Zacks Rank #1 (Strong Buy), Varian Medical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Abiomed reported fourth-quarter fiscal 2018 earnings per share of 80 cents, which beat the Zacks Consensus Estimate by 25%. Revenues were $174.4 million, beating the Zacks Consensus Estimate by 6.3%.
Varian Medical reported second-quarter fiscal 2018 adjusted earnings per share of $1.15, which beat the Zacks Consensus Estimate of $1.06. Revenues totaled $729.9 million, which surpassed the Zacks Consensus Estimate of $659.6 million.
Intuitive Surgical reported first-quarter 2018 adjusted earnings per share of $2.44, which beat the Zacks Consensus Estimate by 22.6%. Revenues totaled $848 million, also surpassing the Zacks Consensus Estimate by 10.6%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>